#USA #DJS Law Group #Eastchester #REGENXBIO #RGX-111

Regenxbio Faces Legal Action for Securities Violations

The DJS Law Group has officially announced a class action lawsuit against REGENXBIO Inc. (NASDAQ: RGNX), centering around alleged violations of securities law. This lawsuit highlights serious concerns among investors regarding the company's transparency and sincerity in communication regarding its drug candidate, RGX-111.

Background of the Case

The legal action stems from allegations that REGENXBIO misled investors during the class period spanning from February 9, 2022 to January 27, 2026. Central to the case is the company's optimistic portrayal of the safety and effectiveness of RGX-111, a product candidate that has since come under scrutiny after a clinical trial participant developed a tumor, leading the FDA to place a clinical hold on the trial.

DJS Law Group asserts that during the class period, REGENXBIO consistently made positive public statements about RGX-111 while failing to disclose critical adverse information related to its safety. The complaint indicates that these omissions present a significant breach of investors' trust, suggesting that the public statements made by the company were not only misleading but fundamentally deceptive.

Impact on Investors

Investors who purchased shares of REGENXBIO during the specified class period are encouraged to consider their involvement in this lawsuit. The DJS Law Group is actively seeking to appoint lead plaintiffs, although participation in the class does not necessitate such an appointment. This is crucial as the suit aims to provide a measure of recovery for those who may have incurred losses due to the alleged securities violations.

As the deadline for potential lead plaintiff appointments looms, set for April 14, 2026, affected investors are urged to reach out to the DJS Law Group to explore their rights and options.

Why Choose DJS Law Group?

DJS Law Group specializes in securities law, focusing on litigation surrounding class actions and corporate governance litigation. Their track record includes successful representation of some of the world’s largest hedge funds and alternative asset managers. The firm’s goal is to enhance investor return through thorough counsel and dedicated representation in court.

By centering on such high-stakes legal matters, DJS Law Group emphasizes that the litigation claims of their clients are invaluable assets that must be handled with care and diligence.

Conclusion

As the case against REGENXBIO unfolds, it marks an essential chapter in the ongoing dialogue about corporate accountability and the rights of investors. With significant investor interests at stake, the outcome could potentially shape the future of securities law practices in the biotech sector. Shareholders are reminded of the importance of staying informed and proactive in the face of potential legal challenges, particularly those that might threaten their investments.

For further inquiries or assistance regarding participation in the lawsuit, contact David J. Schwartz at DJS Law Group, located in Eastchester, NY.